Leukemia

DF/HCC白血病项目继续专注于推进对分子生物学的理解， 发病机制作为一种手段，以确定新的途径和蛋白质的目标，可以被抑制，以改善 急性白血病、骨髓增生异常综合征和骨髓增生性肿瘤患者的结局。的 该计划的长期目标是加速将新发现从实验室转化为 临床，首先进入动物模型的临床前测试，然后进入创新的，由制药商发起的I期或11期 临床试验该计划的具体目标是：1）确定新的细胞和分子机制， 有助于白血病和相关疾病的发病机制; 2）产生准确的动物模型， 白血病，以提高对发病机制的理解并开发靶向抗白血病药物;以及3） 设计和实施临床试验，以转化白血病领域的实验室研究发现， 癌症中心和整个癌症中心。 白血病项目自2000年以来一直由CCSG资助。该计划获得了优异的成绩 在2005年最后一次竞争性审查时。60名计划成员代表四个部门， HMS，HSPH的一个部门和六个DF/HCC成员机构。该方案继续 资金充足，有3560万美元的同行评审资金，其中1600万美元来自NCI，1960万美元来自NCI。 200万美元为其他同行审议资金（2009年，费用总额）。项目成员有879名与项目有关的成员 从2006年到2010年出版。其中16%是程序内交互，43%是 27%是跨方案的，27%是跨机构的。

The DF/HCC Leukemia Program continues to focus on advancing the understanding of molecular pathogenesis as a means to define novel pathways and protein targets that can be inhibited to improve the outcome of patients with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms. The long-range goal of the Program is to accelerate the translation of novel discoveries from the laboratory to the clinic, first into preclinical testing in animal models and then into innovative, investigator-initiated Phase I or 11 clinical trials. The Program's Specific Aims are: 1) to identify novel cellular and molecular mechanisms that contribute to the pathogenesis of leukemia and related diseases; 2) to generate accurate animal models of leukemia to improve the understanding of pathogenesis and to develop targeted anti-leukemic agents; and 3) to design and implement clinical trials to translate laboratory research discoveries made within the Leukemia Program and the Cancer Center as a whole. The Leukemia Program has been CCSG funded since 2000. The Program received an outstanding merit score at the time of the last competitive review in 2005. The 60 Program members represent four departments of HMS, one department of HSPH and six DF/HCC member institutions. The Program continues to be well-funded with $35.6 million in peer-reviewed funding, of which $16 million was from the NCI and $19.6 million was other peer reviewed funding (2009, total costs). Program members had 879 in Program-relevant publications from 2006 through 2010. Of these 16% were intra-programmatic interactions, 43% were inter-programmatic and 27% were inter-institutional.